These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 33221918)
1. Fracture risk in systemic lupus erythematosus patients over 28 years. Garelick D; Pinto SM; Farinha F; Pires T; Khan E; Isenberg D Rheumatology (Oxford); 2021 Jun; 60(6):2765-2772. PubMed ID: 33221918 [TBL] [Abstract][Full Text] [Related]
2. Vitamin D and bisphosphonate therapy in systemic lupus erythematosus patients who receive glucocorticoids: are we offering the best care? Sapkota S; Baig S; Hess T; O'Connell AM; Menk J; Shyne M; Fazeli P; Ensrud K; Shmagel A Lupus; 2020 Mar; 29(3):263-272. PubMed ID: 31996109 [TBL] [Abstract][Full Text] [Related]
3. Low rate of densitometric diagnosis and treatment in patients with severe osteoporosis in Colombia. Fernández-Ávila DG; Rincón-Riaño DN; Pinzón DF; Gutiérrez Dávila JM Arch Osteoporos; 2019 Sep; 14(1):95. PubMed ID: 31486920 [TBL] [Abstract][Full Text] [Related]
4. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan. Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078 [TBL] [Abstract][Full Text] [Related]
5. Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures. Aguado-Maestro I; Panteli M; García-Alonso M; Bañuelos-Díaz A; Giannoudis PV Injury; 2017 Dec; 48 Suppl 7():S27-S33. PubMed ID: 28851521 [TBL] [Abstract][Full Text] [Related]
6. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. Rossini M; Viapiana O; Vitiello M; Malavolta N; La Montagna G; Maddali Bongi S; Di Munno O; Nuti R; Manzini CU; Ferri C; Bogliolo L; Mathieu A; Cantatore F; Del Puente A; Muratore M; Grassi W; Frediani B; Saviola G; Delvino P; Mirone L; Ferraccioli G; Tripi G; Piazza I; Gatti D Reumatismo; 2017 May; 69(1):30-39. PubMed ID: 28535619 [TBL] [Abstract][Full Text] [Related]
7. [Therapy of glucocorticoid induced osteoporosis]. Arazzi M; Di Fulvio G; Di Pietro LO; Grabocka X; Longo MO; Micioni G; Pezzutto A; Piscitani L; Schiazza A; Silvestri S; Vigilante G; Amoroso L; Bonomini M G Ital Nefrol; 2017 Dec; 34(Nov-Dec):. PubMed ID: 29207221 [TBL] [Abstract][Full Text] [Related]
12. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs. Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273 [TBL] [Abstract][Full Text] [Related]
13. Prevalence and predictors of low bone density and fragility fractures in women with systemic lupus erythematosus in a Mediterranean region. Salman-Monte TC; Torrente-Segarra V; Muñoz-Ortego J; Mojal S; Carbonell-Abelló J Rheumatol Int; 2015 Mar; 35(3):509-15. PubMed ID: 25030324 [TBL] [Abstract][Full Text] [Related]
14. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640 [TBL] [Abstract][Full Text] [Related]
15. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Buckley L; Guyatt G; Fink HA; Cannon M; Grossman J; Hansen KE; Humphrey MB; Lane NE; Magrey M; Miller M; Morrison L; Rao M; Robinson AB; Saha S; Wolver S; Bannuru RR; Vaysbrot E; Osani M; Turgunbaev M; Miller AS; McAlindon T Arthritis Rheumatol; 2017 Aug; 69(8):1521-1537. PubMed ID: 28585373 [TBL] [Abstract][Full Text] [Related]
16. Bone mineral density changes in women with systemic lupus erythematosus. Boyanov M; Robeva R; Popivanov P Clin Rheumatol; 2003 Oct; 22(4-5):318-23. PubMed ID: 14579164 [TBL] [Abstract][Full Text] [Related]
19. Evaluation and Treatment of Osteoporosis. O'Connor KM Med Clin North Am; 2016 Jul; 100(4):807-26. PubMed ID: 27235616 [TBL] [Abstract][Full Text] [Related]
20. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status. Mok J; Brown C; Moore AEB; Min SS; Hampson G Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]